COYA - Coya Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

COYA

COYA THERAPEUTICS, INC.

NASDAQ

$4.95

▼ DOWN 0.80% (-0.04)

KEY STATISTICS

Market Cap$116.82 M

52w High$7.75

52w Low$3.71

Dividend Yield—

Frequency—

P/E-4.76

Volume151.82K

Shares Out.23.46M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Arun Swaminathan

COMPENSATION 2026

Salary$546,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$2,091,007

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 29, 2022

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$12.00

Target Low$12.00

Target Median$12.00

Target Consensus$12.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$110.00K

NOV

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

33.83%

HOLDERS

TOP 8 OF 77 · RANKED BY POSITION SIZE

Dme Capital Management, LP

2.3M sh

$9.2M

Greenlight Capital Inc

1.3M sh

$9.44M

Aigh Capital Management LLC

Alyeska Investment Group, L.P.

800.0K sh

$3.15M

Awm Investment Company, Inc.

725.0K sh

$4.21M

Prosight Management, LP

PRICE

$4.95 ▼ DOWN 0.80% (−$0.04)

About Coya Therapeutics, Inc.

https://www.coyatherapeutics.com ↗

Coya Therapeutics, a clinical-stage biotech founded in 2020, develops Treg-based therapies—including biologics, exosomes, and cell therapies—for neurodegenerative, autoimmune, and metabolic diseases.

INDUSTRY

Biotechnology

A PRODUCT COYA THERAPEUTICS, INC. IS KNOWN FOR

COYA 302

Coya Therapeutics' lead investigational biologic combines therapies to boost regulatory T cell anti-inflammatory functions, aiming to treat neurodegenerative diseases like ALS, Frontotemporal Dementia, and Parkinson's Disease.

COMPETITORS

COMPETITOR

Coya Therapeutics in 2025

SENTIMENT: − NEGATIVE

MARKET EVENT · OCTOBER 2025

Coya Therapeutics' Stock Dips Following Announcement of Upsized $23 Million Public Offering

In late October 2025, Coya Therapeutics announced the pricing of an upsized public offering of its common stock, ultimately raising approximately $23.0 million. This event drew significant attention as it involved substantial dilution for existing shareholders and had an immediate negative impact on the company's stock price.

PRODUCT LAUNCH · Q3-Q4 2025 · IN PROGRESS

Coya Therapeutics Advances Lead Candidate COYA 302 into Phase 2 Clinical Trial for ALS and Expands Geographically

In 2025, Coya Therapeutics initiated its pivotal Phase 2 ALSTARS clinical trial for COYA 302 in patients with Amyotrophic Lateral Sclerosis (ALS), a significant step in its product development pipeline. [8, 9] The company further expanded the trial's reach by gaining regulatory approval from Health Canada to include clinical sites in Canada, broadening the potential patient pool and accelerating enrollment. [7, 23] This represents the most significant strategic decision of the year, committing substantial capital and operational focus to advancing its lead therapeutic candidate towards potential commercialization.

Latest News

BUSINESS WIRE · OCT 5, 2026

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company's Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya's combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral scle.

READ ARTICLE